Answers are grounded in this paper and cite their sources.
Alzheimer's disease (AD) is the most common form of dementia affecting 35 million individuals worldwide. Current AD treatments provide only brief symptomatic relief. It is therefore urgent to replace this symptomatic approach with a curative one. Increasing serotonin signaling as well as developing molecules that enhance serotonin concentration in the synaptic cleft have been debated as possible therapeutic strategies to slow the progression of AD. In this Viewpoint, we discuss exciting new insights regarding the modulation of serotonin signaling for AD prevention and therapy.
No takes yet. Share an insight, caveat, or question.
Claeysen et al. (2015) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: